Turn­stone charts $75M IPO for TIL cell ther­a­pies in drum­roll of biotech IPOs this month

Turn­stone Bi­o­log­ics plans to list on the Nas­daq in a $75 mil­lion raise short­ly af­ter a trio of biotechs — Apogee Ther­a­peu­tics, Sagimet Bio­sciences and 60 De­grees Phar­ma­ceu­ti­cals — went pub­lic fol­low­ing a stretch of in­ac­tiv­i­ty for the be­lea­guered sec­tor.

The sol­id tu­mor cell ther­a­py biotech hopes to mark a turn­around af­ter los­ing key deals with Ab­b­Vie in 2021 and Take­da in 2022 and en­act­ing lay­offs last year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER